BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 20735440)

  • 1. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
    Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
    Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
    Koike N; Pilon-Thomas S; Mulé JJ
    J Immunother; 2008 May; 31(4):402-12. PubMed ID: 18391755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
    Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
    Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses.
    Highton AJ; Girardin A; Bell GM; Hook SM; Kemp RA
    BMC Immunol; 2016 Oct; 17(1):39. PubMed ID: 27756214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
    Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
    Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
    Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
    Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.